Mobile

A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C. Stud...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004720-20

A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C. Studio di fase 3 con 2 regimi di dosaggio di Telaprevir in combinazione con Peginterferone Alfa-2a (Pegasys) e Ribavirina (Copegus) in soggetti naive con epatite C cronica 1 genotipo 1

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the efficacy of telaprevir in combination with peginterferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-naive subjects with genotype 1 chronic hepatitis C. Dimostrare l'efficacia del telaprevir in combinazione con peginterferone alfa-2a (Peg-IFN-alfa-2a) e ribavirina (RBV) in soggetti naive affetti da epatite C cronica genotipo 1

Critère d'inclusion

  • Chronic Hepatitis C genotype 1,epatite C cronica genotipo 1

Liens